TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38597864
Drug: AT-001 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-001 (selective aldose reductase inhibitor) administered twice daily for 15 months
Study: 38597988
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg oral THC
Study: 38598227
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (100 impulses of 0.1mJ/mm/cm2 in gastrocnemius muscle, 3 times weekly for 3 weeks)
Study: 38598227
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (no shockwaves delivered)
Study: 38598229
Drug: Guselkumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (subcutaneous injections at FDA-approved dosing schedule for psoriasis over 24 weeks)
Study: 38598516
Drug: Parsaclisib +
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib + rituximab (Treatment A)
Study: 38598516
Drug: Parsaclisib +
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib + rituximab + bendamustine (Treatment B)
Study: 38598516
Drug: Parsaclisib +
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib + ibrutinib (Treatment C)
Study: 38598572
Drug: Lixisenatide (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (daily subcutaneous for 12 months)
Study: 38598710
Drug: Myeloablative consolidation
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative consolidation (for those who completed therapy)
Study: 38598710
Drug: Nonmyeloablative consolidation
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmyeloablative consolidation (for those who completed therapy)
Study: 38599257
Drug: Technology-assisted Web
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Technology-assisted Web App for self-selection of nonprescription statin treatment
Study: 38599653
Drug: SARS-CoV-2 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccines in IMIDs patients
Study: 38599653
Drug: SARS-CoV-2 vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccines in healthy controls (HC)
Study: 38599653
Drug: Post-immunisation anti-RBD
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-immunisation anti-RBD levels <6000 binding antibody units/mL
Study: 38599799
Drug: Maternal medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal medicines
Study: 38599800
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral administration of 10,000 IU vitamin D
Study: 38600278
Drug: High antihypertensive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antihypertensive medication burden (≥3 different classes of prescribed antihypertensive medications)
Study: 38600278
Drug: High antihypertensive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antihypertensive medication burden in the standard group
Study: 38600278
Drug: High antihypertensive
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antihypertensive medication burden in the intensive group
Study: 38600471
Drug: binimetinib 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: binimetinib 45 mg BID plus nivolumab 480 mg Q4W
Study: 38600501
Drug: Pedicled buccal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pedicled buccal periosteal flap for closure of oroantral fistula
Study: 38600507
Drug: GFH018 5-85
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFH018 5-85 mg BID (14d-on/14d-off)
Study: 38600507
Drug: GFH018 85
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFH018 85 mg BID (7d-on/7d-off)
Study: 38600599
Drug: CPT medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT medication management intervention during hospitalization with follow-up post-discharge and communication with circle of care
Study: 38601063
Drug: Subsequent infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent infusions of Lu-177-DOTATATE (reduced doses)
Study: 38601485
Drug: utidelone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: utidelone (40 mg/m2)
Study: 38601830
Drug: Clavulanic Acid
Normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clavulanic Acid (CLAV) 500 mg/day
Study: 38602417
Drug: KIN-3248 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIN-3248 (5 to 50 mg orally daily)
Study: 38602618
Drug: Premixed group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premixed group (group M): 12 mg of hyperbaric bupivacaine, 20 mcg of fentanyl, and 100 mcg of morphine injected as a single mixture.
Study: 38602618
Drug: Separate injection
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate injection group (group S): Same drugs in separate injections.
Study: 38602658
Drug: Integrated self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated self-management behaviors (including CGM usage, frequent glucose testing, insulin pump usage, carbohydrate counting application, adjustment of insulin doses, and usage of apps for diabetes management)
Study: 38603800
Drug: Darvadstrocel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darvadstrocel treatment
Study: 38604213
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention plus optimal medical therapy
Study: 38604504
Drug: 1.4 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g/kg/d protein emphasizing unprocessed lean beef (high protein experimental group)
Study: 38604504
Drug: 1.4 g/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g/kg/d protein from mixed food sources (high protein control)
Study: 38604504
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g total protein/kg body weight/day from mixed food sources (normal protein control)
Study: 38604815
Drug: GS-4224 (400-1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-4224 (400-1,500 mg once daily)
Study: 38605166
Drug: FPM-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPM-guided therapy
Study: 38605166
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (previous therapy)
Study: 38605438
Drug: Routine screening
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine screening for plasma BKPyV-DNAemia loads monthly until month 9, then every 3 months until 2 years post-transplant (3 years for children)
Study: 38605438
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of immunosuppression for patients with BKPyV-DNAemia loads >1000 copies/mL or exceeding 10,000 copies/mL, or with biopsy-proven BKPyV-nephropathy
Study: 38605438
Drug: Experimental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatments (antivirals, vaccines, neutralizing antibodies, and adoptive T cells)
Study: 38605470
Drug: Anti-interferon-α antibodies
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-interferon-α antibodies
Study: 38605470
Drug: Anti-interleukin-22 antibodies
Normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-interleukin-22 antibodies
Study: 38605470
Drug: Anti-interleukin-17F antibodies
Normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-interleukin-17F antibodies
Study: 38605658
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of psilocybin (25 mg)
Study: 38605958
Drug: BVAC-C injection
Normalized name: protein C Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVAC-C injection at 0, 4, 8 weeks (Arm 1)
Study: 38605958
Drug: BVAC-C injection
Normalized name: protein C Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVAC-C injection at 0, 4, 8, 12 weeks (Arm 2)
Study: 38605958
Drug: BVAC-C injection
Normalized name: protein C Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BVAC-C injection at 0, 4, 8, 12 weeks with topotecan at 2, 6, 10, 14 weeks (Arm 3)
Study: 38606105
Drug: DNAJB1-PRKACA fusion-based
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DNAJB1-PRKACA fusion-based neoepitope vaccine Fusion-VAC-XS15 combined with anti-PD-L1 antibody atezolizumab
Study: 38606105
Drug: Anti-PD-L1 antibody
Normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Pacmilimab (DB18873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-L1 antibody atezolizumab
Study: 38606621
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) titration during DISE
Study: 38606776
Drug: SingHypertension intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SingHypertension intervention (clinician training, subsidized medications, nurse-delivered motivational conversations, telephone follow-ups)
Study: 38606777
Drug: Apilimod dimesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apilimod dimesylate 125 mg twice daily for 12 weeks
Study: 38606958
Drug: RSVpreF (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF (240 µg with or without aluminum hydroxide)
Study: 39382718
Drug: pembrolizumab-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab-chemotherapy
Study: 38608150
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy (HAIP-SYS)
Study: 38608658
Drug: Pirfenidone (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (escalated from 3×1 to 3×3 capsules of 267 mg/day within 3 weeks for 12 months)
Study: 38608691
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (240 mg every 2 weeks)
Study: 38608691
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (NIVO3 plus IPI1: 3 mg/kg every 2 weeks plus 1 mg/kg every 6 weeks)
Study: 38608691
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (NIVO1 plus IPI3: 1 mg/kg every 3 weeks plus 3 mg/kg every 3 weeks for four cycles then nivolumab 240 mg every 2 weeks)
Study: 38609316
Drug: Elotuzumab administered
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab administered starting on day 4 post-ASCT and then every 28 days until 1 year post-ASCT, combined with autologous lymphocyte infusion and lenalidomide maintenance (cycles 4-12).
Study: 38609316
Drug: Elotuzumab and
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab and autologous lymphocyte infusion post-ASCT.
Study: 38983921
Drug: Remimazolam-based total
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam-based total intravenous anesthesia
Study: 38609987
Drug: Maytenus senegalensis
Normalized name: Khaya senegalensis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maytenus senegalensis (800 mg every 8 hours for 4 days)
Study: 38610031
Drug: Pamiparib 40
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamiparib 40 mg twice daily every 3 weeks for up to 1 year or until disease progression
Study: 38610034
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation with ProPrems® (Bifidobacterium infantis, Bifidobacterium lactis, and Streptococcus thermophilus) diluted in 3 mL breastmilk per day until gestational week 34
Study: 38610034
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 g maltodextrin powder) diluted in 3 mL breastmilk per day until gestational week 34
Study: 38610138
Drug: Staff-facilitated telemedicine
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Staff-facilitated telemedicine model for HCV treatment initiation
Study: 38610925
Drug: Neo-adjuvant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant systemic therapy (NAS) with immunotherapy (anti-PD-1, combination anti-CTLA-4 and anti-PD-1)
Study: 38610925
Drug: Pembrolizumab as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab as NAS therapy (3 doses)
Study: 38610925
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ipilimumab + nivolumab as NAS therapy
Study: 38610950
Drug: sHLA-G levels
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sHLA-G levels in CIN before starting IMQ application
Study: 38611082
Drug: Transperineal Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transperineal Laser Ablation (TPLA) treatment, details on dosage and duration not available
Study: 38611595
Drug: Metabolomic analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolomic analysis at end of induction treatment (D33)
Study: 38613322
Drug: Perioperative immunonutrition
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative immunonutrition (IMN) with oral supplementation enriched with arginine, omega-3 fatty acids, and dietary nucleotides (Group 2)
Study: 38613545
Drug: Flecainide acetate
Normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide acetate oral inhalation solution (FlecIH), single dose administered via oral inhalation over 8 minutes in a supervised medical setting.
Study: 38613938
Drug: Low PPI
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low PPI (< 1.5) and Low Hb (< 9.7 g/dL)
Study: 38614279
Drug: 60 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 Gy in 8 fractions (stereotactic body radiation therapy)
Study: 38614447
Drug: bCBCT augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: bCBCT augmented with intranasal oxytocin (40 international units administered 30 min before each session)
Study: 38614447
Drug: bCBCT augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: bCBCT augmented with intranasal oxytocin
Study: 38614631
Drug: Euvichol-S (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euvichol-S (two 1.5 mL doses)
Study: 38614954
Drug: TBE vaccine
Normalized name: TBE vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBE vaccine (0.5-mL for adults, 0.25-mL for pediatric) administered at 3 visits.
Study: 38615067
Drug: Letermovir 480
Normalized name: letermovir 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir 480 mg daily orally for 28 weeks
Study: 38615070
Drug: Baseline hemagglutination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline hemagglutination antibody inhibition
Study: 38615472
Drug: Temozolomide 75
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 75 mg/m² given every other week (one week on/one week off)
Study: 38615472
Drug: Temozolomide 75
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 75 mg/m²
Study: 38615673
Drug: Intramuscular 85
Normalized name: 85 strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (Group A)
Study: 38615673
Drug: Intramuscular 85
Normalized name: 85 strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional topical ocular administration of CTH522 (Group B)
Study: 38615673
Drug: Intramuscular 85
Normalized name: 85 strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional intradermal administration of CTH522 (Group C)
Study: 38615673
Drug: Intramuscular 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 15 μg CTH522-CAF01, two boosters at day 28 and 112 (Group D)
Study: 38615673
Drug: Intramuscular 85
Normalized name: 85 strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 85 μg CTH522-CAF09b, two boosters at day 28 and 112 (Group E)
Study: 38615673
Drug: Intramuscular placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular placebo (Group F)
Study: 38615899
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise training (RET), 16-week, twice-weekly, whole-body intervention
Study: 38616308
Drug: Dasatinib plus
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib plus low-intensity chemotherapy for one month followed by dasatinib monotherapy for two months
Study: 38616308
Drug: Dasatinib-based low-intensity
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib-based low-intensity chemotherapy
Study: 38616411
Drug: BPL-003 (5-methoxy-DMT)
Normalized name: 2-methoxy-5-chloroprocainamide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BPL-003 (5-methoxy-DMT) at doses of 1-12 mg
Study: 38616411
Drug: BPL-003 (5-methoxy-DMT)
Normalized name: 2-methoxy-5-chloroprocainamide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BPL-003 (5-methoxy-DMT) at doses of 10 and 12 mg
Study: 38616438
Drug: RSVpreF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF vaccine (120-µg injection)
Study: 39046635
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of natalizumab
Study: 39046635
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of natalizumab
Study: 38617387
Drug: Therapist-guided internet-delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-delivered cognitive behavioural therapy (ICBT) for 12 weeks
Study: 38617599
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg bid plus spartalizumab 300 mg q3w
Study: 38617784
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus 30 minutes before incision, followed by continuous infusion of 3.0 mg/kg/hour until 2 hours after skin closure)
Study: 38618202
Drug: GST-HG171 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GST-HG171 (150 mg) plus Ritonavir (100 mg)
Study: 38618204
Drug: Dexfadrostat phosphate
Normalized name: dextroamphetamine sulfate Oral Tablet [DextroStat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfadrostat phosphate 4, 8, or 12 mg once daily for 8 weeks
Study: 38618550
Drug: 36 g erythritol
Normalized name: Erythritol
DrugBank: Erythritol (DB04481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 g erythritol daily for 5 weeks
Study: 38618550
Drug: 24 g xylitol
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 g xylitol daily for 5 weeks
Study: 38619037
Drug: Teriflunomide (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide (14 mg adult-equivalent dose)
Study: 38619178
Drug: sirolimus gel
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sirolimus gel
Study: 38620056
Drug: FlexHD prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: FlexHD prophylactic biological mesh using sublay intraperitoneal technique
Study: 38620056
Drug: FlexHD prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: FlexHD prophylactic biological mesh
Study: 38621178
Drug: Low-dose atropine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atropine (various concentrations)
Study: 38621393
Drug: Bictegravir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir (30 mg), Emtricitabine (120 mg), Tenofovir Alafenamide (15 mg) once daily
Study: 38621393
Drug: Bictegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir (50 mg), Emtricitabine (200 mg), Tenofovir Alafenamide (25 mg) upon attaining a bodyweight of at least 25 kg
Study: 38621405
Drug: Aerosol-inhaled live-attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol-inhaled live-attenuated Mycobacterium bovis BCG (BCG Danish strain and BCG Bulgaria strain)
Study: 38621405
Drug: Intradermally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermally administered BCG
Study: 38621575
Drug: Edetate disodium
Normalized name: Edetate Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edetate disodium (EDTA) chelation therapy
Study: 38621624
Drug: SQ-LNS containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS containing 15 mg zinc from ≥3 months before conception (preconception, arm 1)
Study: 38621624
Drug: SQ-LNS containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS containing 15 mg zinc from ∼12 weeks gestation through delivery (early pregnancy, arm 2)
Study: 38621793
Drug: UPA 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPA 15 mg QD
Study: 38621793
Drug: UPA 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPA 30 mg QD
Study: 38621793
Drug: UPA 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPA 15 mg QD and UPA 30 mg QD